2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 353-355
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Biological Therapies, Transplantation, Biological Processes, Immune Mechanism, Diseases, Immunology, GVHD, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, T Cell Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

1061 No evidence of clinical benefit from mycophenolate mofetil use with PTCy-CNI prophylaxis after HLA-matched donor HCT

Rima M. Saliba, PhD, Tao Wang, PhD2, Cuyler Huffman, MS3, Pooja Khandelwal, MD4, Nosha Farhadfar, MD5, Zachariah Defilipp, MD6, Arpita Gandhi, M.D., M.S.7, Fotios Michelis, MD, PhD8, Monzr M. M Al Malki, MD9, Stephen R. Spellman, MBS10, Stephanie J. Lee Jr, MD, MPH11, Najla El Jurdi, MD12, Rohtesh Mehta, MD, MPH13
1 Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, United States
2 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, United States, Division of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, United States
3 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, United States
4 Department of Pediatrics, University of Cincinnati,, Cincinnati, United States, Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, United States
5 Sarah Cannon Transplant & Cellular Program at Methodist Hospital, San Antonio, United States
6 Hematopoietic Cell Transplant and Cellular Therapy Program, Mass General Brigham Cancer Institute, Boston, United States
7 Oregon Health and Science University, Portland, United States
8 Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada
9 City of Hope Cancer Center, Duarte, United States
10 CIBMTR® (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, United States
11 Fred Hutchinson Cancer Center, Seattle, United States
12 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, United States, Immune Deficiency and Cellular Therapy Program, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, United States
13 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, United States, Stem Cell Transplantation and Cellular Therapies, University of Texas, MD Anderson Cancer Center, Houston, United States

Background
Post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GvHD) prophylaxis is frequently combined with a calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF). Whether additional immunosuppression with MMF is needed with the PTCy/CNI backbone in patients undergoing HLA-matched donor hematopoietic cell transplants (HCT) is debatable. We evaluated outcomes of HLA-matched sibling (MSD) or matched unrelated donor (MUD) HCT following PTCy/CNI prophylaxis with or without MMF, using the Center for International Blood & Marrow Transplant Research database.

Methods
Adult patients who underwent first MSD or MUD HCT in the US (2017-2022) for AML, ALL, or MDS with PTCy-CNI prophylaxis were included. Those who received ATG, alemtuzumab, or other GvHD prophylaxis were excluded. The primary endpoint was GvHD-free relapse-free survival (GRFS). Secondary endpoints were grade 2-4 and 3-4 acute (a) GvHD, overall chronic (c) GVHD, cGvHD requiring immunosuppressive systemic therapy (IST), treatment-related mortality (TRM), overall survival (OS), and disease-free survival (DFS). The cumulative incidence of GvHD was estimated considering death before GvHD as a competing risk. Comparison of PTCy-CNI +/- MMF was performed using Cox’s proportional hazards models under the Inverse Probability of Treatment Weighting (IPTW) to correct for potential imbalance between PTCy-CNI +/- MMF groups. Propensity scores were calculated for the entire cohort using logistic regression models. Patients with extreme propensity scores of <.05 or >.95 were excluded. Statistical significance was set at P<0.01 to adjust for multiple testing. Formal interaction tests between MMF use and donor type were significant for DFS (P=0.0094) and relapse (P=0.0040); therefore, all outcomes were evaluated for the overall cohort and stratified by donor type.

Results
2771 patients met inclusion criteria: 2192 (79%) received MMF and 579 (21%) did not. Median age at HCT was 61 years (MMF) and 58 years (no MMF). AML (57% vs 55%) and MDS (26% vs 28%) were the primary diseases; approximately one-fourth (26% vs 27%) had a high/very high refined disease-risk index. MUD (76% vs 69%) and peripheral blood grafts (94%) were predominant in both groups. Myeloablative conditioning was used less commonly in the MMF (46%) vs no-MMF group (67%). The median follow-up among survivors was 37 months (MMF) and 48 months (no-MMF).

In multivariable regression analysis, MMF use was not associated with GRFS (HR 1.03, 95% CI 0.87-1.20, P=0.76), OS (HR 0.88, 95% CI 0.72-1.08, P=0.21), TRM (HR=0.97, 95% CI 0.74-1.26, P=0.80), relapse (HR=0.95, 95% CI 0.81-1.11, P=0.49), or DFS (HR 0.97, 95% CI 0.82-1.14, P=0.69). However, among MSD recipients, MMF use was associated with higher risk for GRFS failure events (HR 1.30, 95% CI 1.02-1.66, P=0.036), DFS events (HR 1.38, 95% CI 1.04-1.82, P=0.024), and relapse (HR 1.51, 95% CI 1.09-2.09, P=0.014) although none reached the pre-specified P<0.01 threshold, but each with the point estimate favoring PTCy-CNI alone. In contrast, among MUD recipients, MMF use was not significantly associated with GRFS (HR 0.95, 95% CI 0.80-1.12, P=0.54), DFS (HR 0.88, 95% CI 0.72-1.07, P=0.21), or relapse (HR 0.83, 95% CI 0.67-1.04, P=0.10). MMF use was associated with a higher risk of overall cGVHD in both the whole cohort (HR 1.34, 95% CI 1.07-1.67, P=0.011) and the MUD subset (HR 1.39, 95% CI 1.06-1.82, P=0.017), though neither met the pre-specified P<0.01 threshold. No significant association was observed in the MSD subset (HR 0.94, 95% CI 0.59-1.51, P=0.81). A similar pattern was observed for IST-requiring cGVHD, with MMF use trending toward a higher risk in the whole cohort (HR 1.29, 95% CI 1.01-1.66, P=0.044) and in the MUD subset (HR 1.34, 95% CI 0.98-1.83, P=0.064), but not in the MSD subset (HR 1.04, 95% CI 0.62-1.74, P=0.89). No significant associations were observed for aGVHD overall or within donor subsets.

Conclusion
The addition of MMF to a PTCy-CNI backbone was not associated with an advantage for any clinical endpoint. Given the consistent absence of benefit coupled with the potential for worsened outcomes, these data challenge the clinical utility of routinely incorporating MMF into PTCy-based prophylaxis for HLA-matched HCT in patients with AML, ALL, or MDS.

Rima M. Saliba, PhD: No relevant conflicts of interest to declare.